Does Cosentyx Affect Flu Vaccine Response?
Cosentyx (secukinumab), an IL-17 inhibitor used for psoriasis, psoriatic arthritis, and ankylosing spondylitis, suppresses parts of the immune system. This can reduce antibody production after flu vaccination, leading to a weaker response.[1][2]
Clinical studies show patients on secukinumab produce fewer flu vaccine antibodies compared to healthy controls. In one trial, peak geometric mean antibody titers were lower across all three flu strains tested, though still above protective thresholds for most patients.[3] Real-world data confirms this immunomodulatory effect persists with ongoing use.[1]
How Strong Is the Impact?
The reduction averages 20-50% in antibody levels versus placebo or untreated groups, depending on the strain and patient factors like age or disease severity.[3][4] Despite this, many achieve seroprotection (adequate antibodies to fight infection).[2] Live attenuated flu vaccines are contraindicated due to immunosuppression risks.[1]
Should You Get the Flu Shot Anyway?
Yes, experts recommend it for Cosentyx users. The vaccine still offers partial protection, better than none, especially during flu season.[1][5] Timing matters: vaccinate before starting Cosentyx if possible, or during treatment with monitoring.[2]
What Do Doctors Check For?
Rheumatologists and dermatologists test post-vaccine antibody titers in high-risk cases (e.g., elderly or comorbidities). No routine adjustment to Cosentyx dosing is needed.[1][4] Report flu-like symptoms promptly, as infection risk may rise slightly.
Patient Experiences and Alternatives
Forum reports and studies note breakthrough flu infections despite vaccination, more common than in non-immunosuppressed people.[6] High-dose or adjuvanted flu vaccines (e.g., Fluzone High-Dose) may boost response better in immunocompromised patients.[5] Discuss pneumococcal and other vaccines with your doctor.
Sources
[1] Cosentyx Prescribing Information (Novartis)
[2] FDA Label for Secukinumab
[3] Journal of Rheumatology: Secukinumab and Influenza Vaccination (2018)
[4] Clinical Infectious Diseases: Immunogenicity in IL-17 Inhibitors (2020)
[5] CDC: Flu Vaccination for Immunocompromised Adults
[6] Arthritis Foundation Patient Reports